ease. CHD or with CHOL/HDLC RATIO 4.8 NON HDL CHOLESTEROL 113 Target for non-HDL cholesterol is 30 mg/dL higher than LDL cholesterol target. HS CRP 0.9 Lower relative cardiovascular risk according to Ama/cnc guidelines. FOr ages >17 ha-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A

8 1759 COC(H/H BBC NBC PLT)( ) ( )8 478 CEA ( )8 334 muumuu:rum ( ) 374 CV, TOTAL ( ) 10231 COMP META PHL ) 167' CORTISOL, TOTAL 4 )8 10124 HS CRP ( ) 859 13, TOTAL ( ) 375 CREATININE ( ) 549 IMBUNOFIXATIOR,S£RUM ( )8 867 14 (THYROXINE) i ( y" 4420 CRP ( )8 571 IRON, TOTAL ( )8 866 14

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.3 Average relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 0.9 Lower relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A

heart disease. CHOL/HDLC RATIO 8.4 H NON HDL CHOLESTEROL 186 H Target for non-HDL cholesterol is 30 mg/dL higher than LDL cholesterol target. HS CRP 0.8 Lower relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.2 mg/dL (talc) <5.0 (talc) <130 mg/dL (talc) mg/L The above test was performed; the specimen was lipemic. Average relative cardiovascular r

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.1 <5.0 (talc) <130 mg/dL (talc) mg/L The above test was performed; the specimen was lipemic. Average relative cardiovascular risk according

dL 11.0-15.0 % 140-400 Thousand/uL 7.5-12.5 fL 1500-7800 cells/uL 850-3900 cells/uL 200-950 cells/uL 15-500 cells/uL 0-200 cells/uL Lab MI HS CRP PERFORMING SITE: MI QUEST DIAGNOSTICS.MIAMI. HMO COMMERCE PARKWAY. MIRAMAR. FL 33015.3938 Laboratocc Outdo': JULIE I. FRIEDMAN.MD.CLIA. IOD0277334

with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.2 Average relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk

ith diabetes plus I major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/c1L) is considered a therapeutic option. HS CRP 1.3 Average relative cardiovascular risk according to MIA/CDC guidelines. For ages >17 hs-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk

ease. CHD or with CHOL/HDLC RATIO 4.8 NON HDL CHOLESTEROL 113 Target for non-HDL cholesterol is 30 mg/dL higher than LDL cholesterol target. HS CRP 0.9 Lower relative cardiovascular risk according to Ama/cnc guidelines. FOr ages >17 ha-CRP mg/L <1.0 1.0-3.0 3.1-10.0 >10.0 Years: Risk A